

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 950)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO DISCLOSEABLE TRANSACTION ACQUISITION OF ASSETS

Reference is made to the announcement made by Lee's Pharmaceutical Holdings Limited (the "Company") dated 9 December 2025 in relation to the acquisition of the Purchased Assets (the "Announcement"). Unless otherwise defined, capitalised terms used in this announcement shall have the same meaning as used in the Announcement.

The Company would like to provide further information as follows:

INFORMATION ON THE PURCHASED ASSETS

Set out below are the revenue and gross profit attributable to the Purchased Assets for the year ended 31 December 2023 and 31 December 2024 that have been extracted from the audited financial statements of the Seller:

	Year ended 31 December	
	2023	2024
	<i>(US\$'000)</i>	<i>(US\$'000)</i>
Revenue	4,584	3,217
Gross Profit	3,997	511

There are expenses incurred in generating the revenue and gross profit attributable to the Purchased Assets. Given that there are excluded items that do not form part of the Purchased Assets acquired by the Purchaser, it is impracticable to separate certain expenses and work out the net profit/net loss (both before and after taxation and extraordinary items) attributable to the Purchased Assets.

This announcement is supplemental to, and should be read in conjunction with the Announcement. The above additional information does not affect other information and content set out in the Announcement.

By order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 22 December 2025

As at the date of this announcement, Ms. Lee Siu Fong (Chairman) and Ms. Leelalertsuphakun Wanee are executive directors of the Company, Dr. Li Xiaoyi, Mr. James Charles Gale and Mr. Huang Zuie-Chin are non-executive directors of the Company, Dr. Chan Yau Ching, Bob, Ms. Cheang Yee Wah, Eva and Dr. Tsim Wah Keung, Karl are independent non-executive directors of the Company.

* *For identification purpose only*